Leerink Partnrs Predicts Sanofi’s Q2 Earnings (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) – Analysts at Leerink Partnrs increased their Q2 2025 EPS estimates for Sanofi in a research report issued to clients and investors on Friday, April 25th. Leerink Partnrs analyst D. Risinger now forecasts that the company will post earnings per share of $0.99 for the quarter, up from their prior estimate of $0.93. The consensus estimate for Sanofi’s current full-year earnings is $4.36 per share. Leerink Partnrs also issued estimates for Sanofi’s Q3 2025 earnings at $1.76 EPS, FY2025 earnings at $4.56 EPS, FY2026 earnings at $5.07 EPS, FY2027 earnings at $5.21 EPS, FY2028 earnings at $5.64 EPS and FY2029 earnings at $6.19 EPS.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.04. The business had revenue of $10.41 billion for the quarter, compared to analyst estimates of $9.79 billion. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. The firm’s revenue was down 11.0% on a year-over-year basis. During the same period last year, the company earned $1.78 EPS.

A number of other analysts also recently weighed in on SNY. The Goldman Sachs Group assumed coverage on shares of Sanofi in a research report on Friday, March 21st. They issued a “neutral” rating and a $65.00 price target on the stock. BNP Paribas began coverage on shares of Sanofi in a research report on Tuesday, April 15th. They set an “outperform” rating and a $65.00 price target on the stock. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Three analysts have rated the stock with a hold rating, two have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $63.33.

Sanofi Price Performance

Shares of SNY opened at $53.72 on Monday. The stock has a market cap of $135.71 billion, a P/E ratio of 21.57, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57. Sanofi has a 1 year low of $45.80 and a 1 year high of $60.12. The stock’s 50-day moving average price is $54.51 and its two-hundred day moving average price is $52.05. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15.

Sanofi Increases Dividend

The business also recently disclosed an annual dividend, which will be paid on Thursday, June 12th. Investors of record on Friday, May 9th will be issued a dividend of $2.0369 per share. This represents a dividend yield of 3.1%. This is a positive change from Sanofi’s previous annual dividend of $1.48. The ex-dividend date is Friday, May 9th. Sanofi’s dividend payout ratio (DPR) is presently 57.14%.

Hedge Funds Weigh In On Sanofi

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Abel Hall LLC lifted its holdings in shares of Sanofi by 1.8% in the fourth quarter. Abel Hall LLC now owns 10,990 shares of the company’s stock valued at $530,000 after purchasing an additional 194 shares in the last quarter. Cardinal Capital Management raised its position in Sanofi by 0.3% in the 1st quarter. Cardinal Capital Management now owns 69,004 shares of the company’s stock valued at $3,827,000 after buying an additional 199 shares during the last quarter. Gradient Investments LLC lifted its stake in Sanofi by 2.1% in the 1st quarter. Gradient Investments LLC now owns 9,764 shares of the company’s stock valued at $542,000 after acquiring an additional 200 shares in the last quarter. Providence Capital Advisors LLC boosted its position in Sanofi by 0.4% during the 4th quarter. Providence Capital Advisors LLC now owns 55,001 shares of the company’s stock worth $2,653,000 after acquiring an additional 201 shares during the last quarter. Finally, Perigon Wealth Management LLC grew its stake in shares of Sanofi by 3.1% during the 1st quarter. Perigon Wealth Management LLC now owns 6,618 shares of the company’s stock worth $367,000 after acquiring an additional 201 shares in the last quarter. 14.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.